This study is testing a new medicine called dupilumab for people 18 and older with a type of Ulcerative Colitis (UC), which is a condition that causes sores in the colon. The study will compare dupilumab to a placebo, which looks like the medicine but has no active ingredients. Participants must have a specific type of UC, where certain cells called eosinophils are involved.
The study lasts up to 68 weeks. It includes a 2 to 4-week screening period, a 52-week treatment period, and a 12-week follow-up. Those who qualify may also receive dupilumab openly during the study.
- Participants will need to be involved for over a year, including multiple visits.
- Dupilumab is compared to a placebo; participants might receive either.
- There are specific criteria to join, and some medical conditions might exclude participation.
It’s important to talk to your doctor to see if this study is right for you and to understand all the risks and benefits. This summary does not include all details, so ask all your questions before deciding to join.